PTAB changes prompt a new strategy for patent owners
On December 9, 2020, the US Patent and Trademark Office (USPTO) published some final rules in the Federal Register, relating to proceedings under the America Invents Act (AIA). For the most part, these rules codified existing Patent Trial and Appeal Board (PTAB) practice relating to whether and how the PTAB institutes an inter partes review (IPR) or a post-grant review (PGR) proceeding, and to the ability of a petitioner and a patent owner to address a PTAB decision on institution.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 July 2020 The US Patent Trial and Appeal Board (PTAB) can put forward its own grounds for halting a petitioner’s bid to amend its patent during a validity trial, according to an agency leadership panel.
22 January 2016 The Patent Trial and Appeal Board may not be the “death squad for patents” it was once described as, with a report revealing that patentees are surviving in more than 66% of cases.